Meta-analysis of natural therapies for hyperlipidemia: Plant sterols and stanols versus policosanol

被引:91
作者
Chen, JT
Wesley, R
Shamburek, RD
Pucino, F
Csako, G
机构
[1] Purdue Univ, Sch Pharm & Pharmacal Sci, W Lafayette, IN 47907 USA
[2] NHLBI, Dept Pharm, Bethesda, MD 20892 USA
[3] NHLBI, Biostat & Clin Epidemiol Serv, Bethesda, MD 20892 USA
[4] NHLBI, Dept Lab Med, Bethesda, MD 20892 USA
[5] NHLBI, Mol Dis Branch, Bethesda, MD 20892 USA
[6] NIH, Dept Hlth & Human Serv, Warren G Magnuson Clin Ctr, Bethesda, MD USA
来源
PHARMACOTHERAPY | 2005年 / 25卷 / 02期
关键词
hyperlipidemia; policosanol; plant sterols; plant stanols; natural therapy; cholesterol; hypercholesterolemia; LDL;
D O I
10.1592/phco.25.2.171.56942
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To compare the efficacy and safety of plant sterols and stanols as well as policosanol in the treatment of coronary heart disease, as measured by a reduction in low-density lipoprotein cholesterol (LDL) levels. Design. Systematic review and meta-analysis of randomized controlled trials. Patients. A total of 4596 patients from 52 eligible studies. Measurements and Main Results. We searched MEDLINE, EMBASE, the Web of Science, and the Cochrane Library from January 1967-June 2003 to identify pertinent studies. Reduction of LDL levels was the primary end point; effects on other lipid parameters and withdrawal of study patients due to adverse effects were the secondary end points. Weighted estimates of percent change in LDL were -11.0% for plant sterol and stanol esters 3.4 g/day (range 2-9 g/day [893 patients]) versus -2.3% for placebo (769 patients) in 23 eligible studies, compared with -23.7% for policosanol 12 mg/day (range 5-40 mg/day [1528 patients]) versus -0.11% for placebo (1406 patients) in 29 eligible studies. Cumulative p values were significantly different from placebo for both (p<0.0001). The net LDL reduction in the treatment groups minus that in the placebo groups was greater with policosanol than plant sterols and stanols (-24% versus -10%, p<0.0001). Policosanol also affected total cholesterol, high-density lipoprotein cholesterol (HDL), and triglyceride levels more favorably than plant sterols and stanols. Policosanol caused a clinically significant decrease in the LDL:HDL ratio. Pooled withdrawal rate due to adverse effects and combined relative risk for patients who withdrew were 0% and 0.84, respectively (95% confidence interval [CI] 0.36-1.95, p=0.69), for plant sterols and stanols across 20 studies versus 0.86% and 0.31, respectively (95% CI 0.20-0.48, p<0.0001), for policosanol across 28 studies. Conclusion. Plant sterols and stanols and policosanol are well tolerated and safe; however, policosanol is more effective than plant sterols and stanols for LDL level reduction and more favorably alters the lipid profile, approaching antilipemic drug efficacy.
引用
收藏
页码:171 / 183
页数:13
相关论文
共 86 条
  • [1] ABRAMOWICZ M, 2003, MED LETTER DRUGS THE, V45, P17
  • [2] Andersson A, 1999, EUR HEART J SUPPL, V1, pS80
  • [3] EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE-II HYPERCHOLESTEROLEMIA
    ANEIROS, E
    MAS, R
    CALDERON, B
    ILLNAIT, J
    FERNANDEZ, L
    CASTANO, G
    FERNANDEZ, JC
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1995, 56 (02): : 176 - 182
  • [4] EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT
    ANEIROS, E
    CALDERON, B
    MAS, R
    ILLNAIT, J
    CASTANO, G
    FERNANDEZ, L
    FERNANDEZ, JC
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1993, 54 (03): : 304 - 312
  • [5] Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients
    Arruzazabala, ML
    Molina, V
    Mas, R
    Fernández, L
    Carbajal, D
    Valdés, S
    Castaño, G
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2002, 29 (10) : 891 - 897
  • [6] DOPPLER-ULTRASOUND PILOT-STUDY OF THE EFFECTS OF LONG-TERM POLICOSANOL THERAPY ON CAROTID-VERTEBRAL ATHEROSCLEROSIS
    BATISTA, J
    STUSSER, R
    PENICHET, M
    UGUET, E
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1995, 56 (09): : 906 - 914
  • [7] Batista JF, 1996, ADV THER, V13, P137
  • [8] Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy
    Blair, SN
    Capuzzi, DM
    Gottlieb, SO
    Nguyen, T
    Morgan, JM
    Cater, NB
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (01) : 46 - 52
  • [9] BLOMQVIST SM, 1993, NUTR METAB CARDIOVAS, V3, P158
  • [10] Canetti M, 1995, INT J CLIN PHARM RES, V15, P159